Vancomycin is an antibacterial drug

FIRVANQ is a glycopeptide antibacterial indicated in adults and pediatric patients less than 18 years of age for the treatment of: ( 1)

• Clostridium difficile‑associated diarrhea
• Enterocolitis caused by Staphylococcus aureus(including methicillin‑resistant strains)

Important Limitations of Use:

• Orally administered vancomycin hydrochloride is not effective for treatment of other types of infections.

See full presribing information

The most common adverse reactions (≥ 10%) were nausea (17%), abdominal pain (15%), and ® ® The most common adverse reactions (≥ 10%) were nausea (17%), abdominal pain (15%), and hypokalemia (13%).

Hypersensitivity to vancomycin

• FIRVANQ must be given orally for treatment of C. difficile‑associated diarrhea and staphylococcal enterocolitis. Orally administered vancomycin hydrochloride is not effective for treatment of other types of infections. ( 5.1)
• Clinically significant serum concentrations have been reported in some patients who have taken multiple oral doses of vancomycin hydrochloride for C. difficile‑associated diarrhea. Monitoring of serum concentrations may be appropriate in some instances. ( 5.2)
• Nephrotoxicity has occurred following oral vancomycin hydrochloride therapy and can occur either during or after completion of therapy. The risk is increased in geriatric patients. Monitor renal function. ( 5.3)
• Ototoxicity has occurred in patients receiving vancomycin hydrochloride. Assessment of auditory function may be appropriate in some instances. ( 5.4) 
• Severe Dermatologic Reactions: Discontinue FIRVANQ at the first appearance of skin rashes, mucosal lesions, or blisters. ( 5.5)
• Prescribing FIRVANQ in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. ( 5.7)